Literature DB >> 1539402

Complications of renal extracorporeal shock wave lithotripsy reviewed.

S Krysiewicz1.   

Abstract

Renal extracorporeal shock wave lithotripsy (ESWL) is a noninvasive and effective method for the treatment of a variety of urinary tract calculi with significantly lower morbidity than both surgical procedures for stone removal (pyelolithotomy/ureterolithotomy) and percutaneous nephrostolithotomy. Though significant, severe complications are rare, ESWL therapy can result in a wide spectrum of tissue injury. This article serves to review the currently known complications of ESWL, which radiologists may encounter, providing an understanding of the potential effects of shock waves on body organs and the resultant functional and morphologic changes that may result.

Entities:  

Mesh:

Year:  1992        PMID: 1539402     DOI: 10.1007/bf02924608

Source DB:  PubMed          Journal:  Urol Radiol        ISSN: 0171-1091


  4 in total

1.  Blood pressure changes after extracorporeal shock wave nephrolithotripsy: prediction by intrarenal resistive index.

Authors:  R Knapp; F Frauscher; G Helweg; W Judmaier; H Strasser; G Bartsch; D zur Nedden
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

2.  Evaluation of the urinary podocalyxin and nephrin excretion levels to determine a safe time interval between two sessions of SWL for renal stones: a non randomized exploratory study.

Authors:  Hüseyin Kocatürk; Nursen Atasoy; Fevzi Bedir; İbrahim Karabulut; Engin Şebin; Kemal Sarica
Journal:  Int Urol Nephrol       Date:  2019-07-18       Impact factor: 2.370

3.  Evaluation of adrenomedullin levels in renal parenchyma subjected to extracorporeal shockwave lithotripsy.

Authors:  Kemal Sarica; Ibrahim Sari; Ayşe Balat; Ahmet Erbağci; Cihanser Yurtseven; Faruk Yağci; Metin Karakök
Journal:  Urol Res       Date:  2003-06-26

4.  Effects of shock wave lithotripsy on plasma and urinary levels of nitrite and adrenomedullin.

Authors:  Kemal Sarica; Ayse Balat; Ahmet Erbagci; Mustafa Cekmen; Muhittin Yurekli; Faruk Yagci
Journal:  Urol Res       Date:  2003-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.